Myeloma Minute: Kicking Off #ASH16

58th Annual ASH Annual Meeting Kicks Off with the IMF's Friday Satellite Symposium

Watch the livestream of the satellite symposium, “Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice,” on Friday, December 2, 2016, beginning at 12:30 p.m. PT / 3:30 p.m. ET. This symposium features leading international myeloma experts who are convened at this year’s 58th Annual American Society of Hematology (ASH) Meeting. Drs. Brian G.M. Durie, S. Vincent Rajkumar, Shaji Kumar, Bruno Paiva, Jesús F. San-Miguel, and Phillipe Moreau debate clinical questions and discuss how these challenges can affect therapeutic decisions faced by clinicians treating myeloma. Accreditation Council for Continuing Medical Education (ACCME) credits are available for physicians participating in this activity. For further details and to explore the entire agenda, click HERE.

The IMF Brings Myeloma Support Group Leaders from Across the Nation to ASH 2016

The IMF brings myeloma support group leaders (SGLs) and patients to San Diego, CA for the 58th Annual American Society of Hematology (ASH) Meeting, an exciting convergence of 20,000 health care professionals from around the world. Start following the IMF ASH team members now on social media as they ramp up to share the latest clinical updates in myeloma research, therapies, and practice strategies online (#ASH16 and #IMFASH16). Enjoy the blogs, videos, pics, and tweets from these dynamic SGLs HERE.

 

IMWG Conference Series from the 58th ASH Annual Meeting in San Diego

Join Drs. Brian G.M. Durie, Joseph Mikhael, and Maria V. Mateos on December 5, 2016 at 8 p.m. PT / 11 p.m. ET as they discuss the latest news and trends in the treatment of Multiple Myeloma at the 58th Annual ASH Meeting in San Diego, California. Watch live HERE.

 

iStopMM and the Black Swan Research Initiative Join Together to Find the Cure

As the IMF’s President and Co-Founder Susie Novis Durie states in this compelling video, “iStopMM and the Black Swan Research Initiative® are ideal partners; iStopMM is part of the Black Swan Research Initiative’s goal to find a cure for myeloma.” What does iStopMM stand for? I is for Iceland, the country. S is for Screens. T is for Treats. O is for Or. And P is for Prevents multiple myeloma. The principal investigator for this project, Dr. Sigurdur Kristinsson, Professor of Blood Diseases at the University of Iceland, explains how adults over the age of 40 in the country of Iceland will be screened for monoclonal gammopathy of undetermined significance (MGUS), the precursor to myeloma. Once those participants in the study are identified as either having MGUS or smoldering multiple myeloma, they will be invited to join a randomized clinical trial to prevent the potential onset of myeloma, or treat the presence of the disease. As Dr. Brian G.M. Durie enthusiastically points out, this early intervention to treat or prevent myeloma may lead to curing the disease. View the full video HERE.

European Commission Grants Conditional Marketing Authorization for Ninlaro (ixazomib)

The European Commission has granted conditional marketing authorization for Ninlaro™ (ixazomib) capsules, in combination with lenalidomide and dexamethasone, for adult patients with multiple myeloma who have received at least one prior therapy. The decision to approve Ninlaro as the first and only oral proteasome inhibitor to treat multiple myeloma follows a positive opinion by the European Medicines Agency (EMA) Committee for Medicinal Products (CHMP) for Human Use in September 2016. Learn more HERE.

Learn How You Can Give to the IMF When You Shop Online

The IMF has a new Amazon link. Whether you shop on Amazon for the holidays or for your daily needs, please bookmark the brand new amazon.myeloma.org., and delete our old Amazon link. At no added cost to you, Amazon will donate a percentage of your total purchase to the IMF. The percentage that Amazon donates to the IMF will continue to increase—even more than 7% at times—depending on how many orders are placed through the IMF portal.

 


We Would Like to Thank Our Sponsors: Takeda Oncology, Celgene, Amgen, and Bristol-Myers Squibb

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.